Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylprednisolone acetate + isopropyl alcohol + povidone-iodine + lidocaine hydrochloride is a corticosteroid combination injection kit marketed as **Dyural L Kit**. The therapeutic core is **methylprednisolone acetate**, a depot synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects primarily through activation of the **glucocorticoid receptor** and downstream suppression of inflammatory gene transcription; **lidocaine hydrochloride** provides local anesthetic activity through blockade of voltage-gated sodium channels, while **isopropyl alcohol** and **povidone-iodine** serve antiseptic preparation roles within the kit. The product is intended for intramuscular, intra-articular, soft tissue, or intralesional administration in a broad set of inflammatory, allergic, dermatologic, rheumatologic, hematologic, autoimmune, and neoplastic conditions aligned with methylprednisolone acetate injectable suspension use. This is a specific multi-component kit formulation rather than plain methylprednisolone acetate alone, and the kit formulation itself has been described as not FDA approved as safe and effective.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylprednisolone acetate + isopropyl alcohol + povidone-iodine + lidocaine hydrochloride.